A Phase 1b Trial of X4P-001 Alone and With Pembrolizumab in Patients With Advanced Melanoma

Trial Profile

A Phase 1b Trial of X4P-001 Alone and With Pembrolizumab in Patients With Advanced Melanoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Apr 2018

At a glance

  • Drugs X4P 001 (Primary) ; Pembrolizumab
  • Indications Malignant melanoma
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors X4 Pharmaceuticals
  • Most Recent Events

    • 18 Apr 2018 As of September 15, 2017, 13 patients have been enrolled, and 11 have completed the study, according to results presented at the 109th Annual Meeting of the American Association for Cancer Research.
    • 18 Apr 2018 Results (n=13) assessing safety and tolerability of X4P-001 in combination with Keytruda (pembrolizumab) in patients with advanced melanoma, were presented at the 109th Annual Meeting of the American Association for Cancer Research.
    • 16 Apr 2018 Results presented in the X4 Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top